Read + Share
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of
JAK/STAT targeting in T-cell lymphomas. Blood 2021;138:2828-2837.
PMID: 34653242
|
 |
|
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of
JAK/STAT targeting in T-cell lymphomas. Blood 2021;138:2828-2837.
PMID: 34653242
|
|
|
|